Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) Net Income towards Common Stockholders: 2020-2023

Historic Net Income towards Common Stockholders for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to -$33.2 million.

  • Therapeutics' Net Income towards Common Stockholders fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • As of Q4 2023, Therapeutics' Net Income towards Common Stockholders stood at -$33.2 million, which was up 2.07% from -$33.9 million recorded in Q3 2023.
  • In the past 5 years, Therapeutics' Net Income towards Common Stockholders ranged from a high of -$12.4 million in Q2 2020 and a low of -$33.9 million during Q3 2023.
  • Over the past 3 years, Therapeutics' median Net Income towards Common Stockholders value was -$21.2 million (recorded in 2022), while the average stood at -$23.5 million.
  • Data for Therapeutics' Net Income towards Common Stockholders shows a maximum YoY plummeted of 56.47% (in 2023) over the last 5 years.
  • Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$12.7 million in 2020, then plummeted by 40.79% to -$17.9 million in 2021, then slumped by 36.27% to -$24.4 million in 2022, then plummeted by 35.96% to -$33.2 million in 2023.
  • Its Net Income towards Common Stockholders stands at -$33.2 million for Q4 2023, versus -$33.9 million for Q3 2023 and -$28.4 million for Q2 2023.